Endocyte prices IPO stock

Back to TopCommentsE-mailPrintBookmark and Share

Endocyte Inc. priced shares for its initial public offering this week, moving one step closer toward raising more than $80 million to fund its cancer drug development.

The West Lafayette-based drug-development firm intends to sell 6.15 million shares for $13 to $15 apiece. That range would fetch $80 million to $92 million.

Those figures include 802,500 shares that will be sold only if demand outstrips the initial allotment of shares of 5.35 million. If Endocyte sells only the smaller amount of shares, it would raise between $70 million and $80 million.

In either case, more than $10 million of the funds will cover Endocyte’s costs in staging the IPO.

Endocyte first indicated in August it would take itself public by selling shares worth $86.3 million, but not until Wednesday did it disclose the price range and number of shares to be sold.

Endocyte operates out of 14,000 square feet at Purdue University Research Park as well as a 4,000-square-foot office in Indianapolis. It is developing six cancer drugs, most of which target cancer cells by binding to their receptors for the compound folate.

Such receptors are “over-expressed” in cancer cells, compared with healthy cells, so Endocyte’s drugs have the potential to be more potent killing the cancers while attacking fewer healthy cells than existing chemotherapy agents.

Endocyte’s leading drug, called EC145, is being tested to treat ovarian cancer that is resistant to platinum-based drugs, as well as to treat non-small-cell lung cancer.

Endocyte launched 15 years ago, based on the research of Philip Low, a Purdue University chemistry professor who serves as Endocyte’s chief science officer.

Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital, Clarian Health Ventures and the Indiana Future Fund.

An even larger investor is the pension fund of the Indianapolis-based Christian Church (Disciples of Christ): It stands to hold nearly 2.5 million shares in Endocyte after the public offering, worth at least $32.2 million. That amount is more than triple the $10.3 million the church invested in Endocyte.

Endocyte will trade on the Nasdaq Global Market under the ticker symbol ECYT.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ